Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal–Child Outcomes
Viruses · 22.03.2025 · 17 (4) · 456
DOI: 10.3390/v17040456 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 22.03.2025. Verfasst von Maryum Imran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow University of Health Sciences, Karachi 74200, Pakistan. Hauptthemen laut MEDLINE: Antiviral Agents, Pregnancy Complications, Infectious, Viral Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Hebammenwesen und Geburtshilfe, Stillen
Abstract (Originalsprache)
Mpox (formerly known as monkeypox), the major public health concern of 2022, has elicited much attention globally. In addition to the usual symptoms observed in smallpox virus infections, infected mothers were found to hold a possible risk of transmission to newborns during delivery. This review aimed to summarize recent clinical trials that involved antiviral therapy, vaccines, immunoglobulin therapy, and other pharmacological interventions specifically for treating infected pregnant women. A comprehensive search was performed using databases such as PubMed, Google Scholar, and Medline to find appropriate disease management strategies. Amongst the vaccines and antivirals being used for treatment, vaccines such as Modified Vaccinia Ankara (MVA/MVA-BN) and Lister clone 16-medium pocket size-8 (LC16m8), while prophylactically effective, have been deemed unsafe for pregnant and lactating females. Antivirals like Tecovirimat, on the other hand, are considered to be a better alternative, but they are not without risks that may outweigh the potential benefits. Additionally, efforts to reduce maternal and fetal complications include administering the MVA-BN vaccine and awareness campaigns regarding herd immunity. Therefore, necessary precautions, prophylactic vaccinations in high-risk outbreak regions, and symptomatic treatment in pregnant and lactating females currently appear to be more feasible approaches against the mpox virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Dow University of Health Sciences, Karachi 74200, Pakistan.
- Department of Medicine, Ziauddin Medical College, Karachi 75000, Pakistan.
- Department of Medicine, Jinnah Sindh Medical University, Karachi 75510, Pakistan.
- Department of Medicine, Bahria University Health Sciences, Karachi 75500, Pakistan.
- Department of Medicine, University of Nairobi, Nairobi P.O. Box 30197-00100, Kenya.
ORCID-Profile: Maryum Imran, Myra Sohail, Javeria Kamran, Syeda Qaima Abbas, Emmanuel Korir
Zitieren
APA
Imran, M., Sohail, M., Kamran, J., Abbas, S. Q., Azeem, K., & Korir, E. (2025). Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal–Child Outcomes. Viruses, 17(4), 456. https://doi.org/10.3390/v17040456
Vancouver
Imran M, Sohail M, Kamran J, Abbas SQ, Azeem K, Korir E. Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal–Child Outcomes. Viruses. 2025;17(4):456. doi:10.3390/v17040456
BibTeX
@article{Imran2025,
author = {Imran, Maryum and Sohail, Myra and Kamran, Javeria and Abbas, Syeda Qaima and Azeem, Khadija and Korir, Emmanuel},
title = {Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal–Child Outcomes},
journal = {Viruses},
year = {2025},
volume = {17},
number = {4},
pages = {456},
doi = {10.3390/v17040456}
}
EUVIMED